Malcolm has spent the last 15 years involved in as a director, manager and investor in early stage technology businesses. His early career was in the speciality division of ICI/Zeneca and he was part of the senior management team involved in the leveraged buyout of the division to form Avecia. Malcolm led Avecia’s entry into the displays and organic semiconductors materials business through the acquisition of Covion Organic Semiconductors GmbH from Hoechst and then went on to establish the polymer electronics team in the UK. He served as a Director of Uniax Inc prior to its acquisition by Dupont. Malcolm managed the Avecia business from 1999 through to its sale to Merck KGaA in 2005 and was then appointed VP of Avecia’s DNA medicines business.
From 2006 to 2009, Malcolm was Managing Director of Liverpool Ventures Ltd responsible for deal origination and portfolio management for a £27m regional seed fund investing in technology-based businesses, including corporate and university spin-outs. From 2009-2011, he was executive chairman of Phoenix Chemicals Ltd, a privately owned fine chemicals supplier to the pharmaceutical industry specialising in continuous chemical processing technology. Since 2011, Malcolm has been an independent consultant working with a number of blue-chip companies, as well as VC-backed start-ups on commercial strategy and business development.